CJC-1295 / Ipamorelin
GHRH + GHRP blend
Research overview
A synergistic combination of a GHRH analog and a selective secretagogue, widely used in GH research protocols.
Descriptions reference published research areas for laboratory context only and are not claims of efficacy, safety, or intended use in humans or animals.
- Price
- $215 CAD
- Purity
- ≥99.3% (HPLC)
- Presentation
- 2×5 mg lyophilized vial
Order / inquire about CJC-1295 / Ipamorelin
Email our research desk for availability, batch Certificates of Analysis, and account setup. We respond to verified research inquiries from Canada only.
Verified Canadian research inquiries only · 18+
For laboratory research use only — not for human or veterinary use
CJC-1295 / Ipamorelin is a chemical reference material sold strictly for in-vitro laboratory research by qualified professionals. It is not a drug, food, cosmetic, or natural health product; it has not been evaluated or approved by Health Canada; and it must never be ingested, injected, or applied to humans or animals. Sold in Canada only, to purchasers 18+. See our Research Use Policy.
Research encyclopedia
Everything the literature has studied.
For laboratory research use only — not for human or veterinary use. The content below summarizes published research context only. It is not medical advice, makes no therapeutic claims, and describes no intended use in humans or animals. These materials have not been evaluated or approved by Health Canada.
What it is
Combination reference preparation pairing a GHRH analog (CJC-1295) with a selective ghrelin-type GH secretagogue (Ipamorelin), designed to stimulate pulsatile GH release through two complementary receptor pathways.
Mechanism of action
CJC-1295 activates the GHRH receptor (adenylate cyclase/cAMP) on somatotrophs; Ipamorelin activates the GH secretagogue receptor GHS-R1a (the ghrelin receptor). Simultaneous stimulation of the two pathways produces a synergistic, amplified GH pulse. Ipamorelin's selectivity means it does not appreciably raise cortisol/ACTH, unlike older GHRPs.
Research areas
- Research in body composition and recovery
- Studies of sleep and tissue regeneration
- GH deficiency models
Studied effects in research models
- Elevation of GH (reported 200-1000%) and IGF-1 (~1.5-3×) under experimental conditions
- Dose-dependent release with no effect on cortisol/ACTH (Ipamorelin selectivity)
Effects listed describe observations reported in laboratory or animal research models only — not outcomes claimed for humans or animals.
Biomarkers tracked in related research
Discovery & background
CJC-1295 was developed by ConjuChem; its Drug Affinity Complex (DAC) technology binds albumin via a bioconjugation to greatly extend half-life. Ipamorelin, a selective GHRP-type secretagogue, was discovered at Novo Nordisk and is notable for not raising ACTH, cortisol, or prolactin at effective GH-releasing doses. The two are combined to exploit distinct receptor pathways.
Considerations & limitations
Research use only. Human data are limited; no Health Canada or FDA approval. Both raise GH/IGF-1, giving a theoretical concern with active malignancy or cancer history, diabetic retinopathy, and edematous states. The DAC variant can drive supraphysiologic IGF-1 — monitor to avoid excessive elevations, plus glucose/insulin and fluid retention. Prohibited by WADA in sport. Require a COA with HPLC/MS identity, blend content/stoichiometry, and endotoxin testing given the risk of mislabeled products.
References
- [1]Teichman et al., 2006 (CJC-1295 GH/IGF-1 in healthy adults) — J Clin Endocrinol Metab; PMID: 16352683
- [2]Raun et al., 1998 (Ipamorelin, selective GH release) — Eur J Endocrinol; PMID: 9849822
- [3]Ionescu & Frohman, 2006 (pulsatile GH by CJC-1295) — J Clin Endocrinol Metab; PMID: 17018654